Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Main SC et al., Cancer Research 2026
cfDNA Methylation Profiling for Metastatic Breast Cancer Detection and ER Classification PMID: 42268298
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Tissue-informed cfMeDIP-seq for simultaneous mBC detection, multi-cancer discrimination, and ER status classification is a meaningful advance over prior single-purpose cfDNA assays |
| Clinical Relevance | 8 | Directly addresses the serial tissue biopsy problem in mBC; ER status reclassification via liquid biopsy has immediate treatment implications |
| Population Reach | 7 | mBC affects ~170,000 US patients; globally ~700,000 new mBC cases annually; ER+/HER2- is the dominant subtype |
| Implementation Speed | 6 | cfMeDIP-seq requires specialized library prep and bioinformatics infrastructure; not trivially deployable at community oncology centers; 3–7 year translation realistic |
| Evidence Strength | 7 | Multi-cohort design, n=713 compendium spanning >10 cancer types, tissue-anchored methodology; limited by abstract-only access and lack of prospective clinical utility data |
Key quantitative result: High accuracy across training, validation, and external cohorts; performance generalized across independent cfMeDIP-seq cohorts and reflected tumor fraction (specific AUC values not reported in abstract).
External validation: Yes — multiple independent cohorts including an external compendium of n=713 samples.
Main limitation: Abstract-only; no prospective clinical utility data demonstrating that ER reclassification changes treatment decisions or outcomes; cfMeDIP-seq not yet standardized for clinical use.
Equity implications: High-income patients with access to specialized cancer centers would benefit first; mBC disproportionately affects younger women and women of color in advanced-stage presentations — this tool could particularly help where repeat biopsy is unsafe or infeasible.
Evidence Maturity: Confirmed → Validated (strong multi-cohort design, but clinical utility not yet demonstrated)
Article 2 — Kurokawa Y et al., Gastric Cancer 2026
JCOG1704 3-Year Follow-Up: Preoperative DOS for Gastric Cancer with Extensive LN Metastasis PMID: 42268543
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | DOS combination is not new, but 3-year durability data confirming a 28-point OS improvement over prior standard in a notoriously difficult-to-treat population is highly meaningful |
| Clinical Relevance | 9 | Already provisionally adopted as standard of care by JCOG; directly changes preoperative chemotherapy decisions in Japan and likely Asia-Pacific |
| Population Reach | 5 | Gastric cancer with bulky/para-aortic nodal disease is a specific subset; globally significant given East Asia's high gastric cancer incidence but narrow patient selection |
| Implementation Speed | 7 | Already provisionally adopted in Japan; DOS agents are generic and available; adoption in Western centers will depend on guideline uptake (2–4 years) |
| Evidence Strength | 6 | Phase II, n=47; durable 3-year OS data are convincing and exceeded a pre-specified historical control threshold, but no randomized comparator; small sample |
Key quantitative result: 3-year OS 86.7% (95% CI 72.7–93.8%) vs 58.8% historical; 3-year PFS 75.6% (95% CI 60.2–85.6%).
External validation: No — single-arm Phase II compared to historical JCOG0405 control; no contemporaneous randomized arm.
Main limitation: n=47 with no randomized comparator; selection bias in who was deemed eligible for potentially curative surgery; results may not generalize outside Japan.
Equity implications: This regimen benefits a Japanese/East Asian patient population with disproportionately high gastric cancer incidence; generic drug access makes it deployable in low/middle-income countries where gastric cancer burden is highest.
Evidence Maturity: Revised → Potentially Practice-Changing (confirmed; provisionally standard in Japan, but Phase III confirmatory trial likely needed for global adoption)
Article 3 — Kim E et al., Eur J Prev Cardiol 2026
CVD Risk in Young Adults with Disabilities: Nationwide Korean Cohort PMID: 42267907
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | While disability-CVD associations are known in older adults, this scale of quantification in young adults (20–39y) with precise disability-type stratification is genuinely novel |
| Clinical Relevance | 7 | Identifies a concrete, actionable target group for early CVD prevention; changes the framing of cardiovascular risk in disability medicine |
| Population Reach | 8 | ~1.3 billion people globally live with some form of disability; young adults represent a long-horizon intervention opportunity; this population is systematically excluded from CVD screening programs |
| Implementation Speed | 7 | No new drug or device needed; existing preventive cardiology tools can be applied immediately once guideline bodies act on this evidence |
| Evidence Strength | 6 | 7.68M cohort, exact 1:10 matching is a significant strength; limited by abstract truncation (specific HRs unavailable), observational design with residual confounding possible, and Korean-specific healthcare context |
Key quantitative result: Significantly elevated composite CVD risk; specific HR values not reported in available abstract.
External validation: Not applicable (nationwide population-level dataset).
Main limitation: Observational; full HR/RR not available; Korean national health data may not generalize to populations with different disability support structures or healthcare access patterns.
Equity implications: Directly serves one of the most systematically underserved groups in preventive medicine; disability populations globally face structural barriers to healthcare access; findings strongest for physical and neurological disability types. Classification confidence downgraded to medium due to truncated abstract.
Evidence Maturity: Confirmed → Validated (large-scale epidemiological evidence; implementation requires guideline translation)
Article 4 — Huang Z et al., Front Immunol 2026
SMARCAL1-Driven Ferroptotic Niche Radiogenomics for MRD-Negative NSCLC Surveillance PMID: 42266691
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | SMARCAL1 as a non-invasive CT radiomic surrogate for ctDNA MRD negativity, with ferroptosis-immune niche mechanism and CRISPR validation, is a genuinely novel mechanistic-radiogenomic synthesis |
| Clinical Relevance | 7 | Addresses the critical gap of adjuvant therapy decision-making in MRD-negative resected NSCLC; could reduce over-treatment or identify patients who would benefit |
| Population Reach | 7 | Early-stage NSCLC is the largest curative-intent lung cancer cohort; ~85,000 resections annually in the US alone |
| Implementation Speed | 5 | Radiomic signatures require standardized CT acquisition protocols; SMARCAL1 pathway validation and prospective trial (NCT05457049) pending; 5–8 year path realistic |
| Evidence Strength | 7 | Three cohorts (derivation n=71 + 2 external validations n=178, n=89); C-index 0.783/0.741 externally; CRISPR functional validation; outperforms 5 comparators in DCA; full text available |
Key quantitative result: HR=0.32 (95% CI 0.18–0.58) for sustained MRD negativity; optimism-corrected C-index 0.798; external C-index 0.783/0.741.
External validation: Yes — two independent external cohorts (TCIA NSCLC-Radiogenomics n=178; Lung3 n=89).
Main limitation: Nested in a single institutional trial; radiomic signature stability across scanner types/protocols not fully established; MRD negativity as surrogate may not directly translate to survival benefit.
Equity implications: Radiomic tools derived from academic center CT protocols may not generalize to community radiology settings with variable equipment; patients in lower-resource settings may benefit from reduced need for serial ctDNA testing if validated.
Evidence Maturity: Confirmed → Validated (strong translational design, but prospective clinical utility trial pending)
Article 5 — Perez D et al., JAMA Dermatol 2026
Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention PMID: 42268603
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Efficacy of nicotinamide for KC prevention established (ONTRAC trial 2015); this adds robust real-world cost-effectiveness evidence, which is novel in the VHA context but not conceptually new |
| Clinical Relevance | 8 | Cost-saving ICER for an OTC oral supplement addresses both clinical and payer decision-making; removes cost as a barrier to prescribing |
| Population Reach | 8 | KC (BCC+SCC) is the most common cancer in the US (~3.5M diagnoses/year); VHA cohort represents a broadly applicable high-risk elderly population |
| Implementation Speed | 9 | Nicotinamide is OTC, inexpensive (~$10–20/month), no prescription required; adoption barrier is awareness and guideline recommendation update only |
| Evidence Strength | 7 | n=33,822 VHA real-world cohort; economic model with QALY calculations; limited by 98% male VHA population, abstract-only access, and observational design |
Key quantitative result: −$58,426 per QALY (cost-saving); 19.9% reduction in KC treatment costs; 624 KCs prevented/year; $364,581 net annual savings.
External validation: VHA cohort represents a distinct real-world population vs the RCT (ONTRAC) that established efficacy; no independent external economic validation.
Main limitation: VHA population is 98% male and predominantly elderly White veterans — limited generalizability to women, younger patients, and racially diverse populations; observational confounding possible.
Equity implications: VHA coverage removes access barriers within that system; nicotinamide's low cost makes it broadly accessible globally; however, the evidence base is almost entirely male, and high-risk populations such as immunosuppressed patients, organ transplant recipients, and people with darker skin tones with different KC risk profiles are underrepresented.
Evidence Maturity: Confirmed → Validated (real-world economic evidence strongly supports implementation)
Article 6 — Liang C et al., Ann Hematol 2026
ML Prediction of Early Death in PTCL-NOS (SEER) PMID: 42268418
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | XGBoost applied to PTCL-NOS early death is modestly novel; ML prognostic models in lymphoma are not new but this specific endpoint and subtype combination is underexplored |
| Clinical Relevance | 6 | Early death risk stratification in aggressive T-cell lymphoma could guide upfront treatment intensity; useful but not immediately practice-changing |
| Population Reach | 4 | PTCL-NOS is rare (~1,500–2,000 new US cases/year); high unmet need within the subtype |
| Implementation Speed | 5 | 7-variable model uses clinically accessible data; but SEER-based model needs prospective validation before clinical use |
| Evidence Strength | 6 | n=1,156 SEER; AUROC 0.842/0.774 training/validation; held-out validation set used; limited by administrative data (no molecular features) |
Key quantitative result: AUROC 0.842 (training), 0.774 (validation).
External validation: Internal held-out split only; no external institutional validation.
Main limitation: SEER lacks molecular/genomic stratification and treatment detail; no prospective validation; AUROC 0.774 in validation is modest.
Equity implications: SEER data captures a diverse US population but lacks granularity on socioeconomic status and treatment access disparities that strongly affect PTCL outcomes.
Evidence Maturity: Confirmed → Validated (within SEER limitations; prospective validation needed for clinical use)
Article 7 — Zheng Y et al., Ann Hematol 2026
KIT/FLT3-ITD Mutations Do Not Predict Outcomes in Pediatric CBF-AML (C-HUANAN) PMID: 42268406
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Directly challenges the widely used mutation-based risk escalation paradigm in CBF-AML; reinforces MRD supremacy; important negative finding from a large multicenter cohort |
| Clinical Relevance | 8 | Has immediate clinical implications for pediatric AML risk stratification: could reduce unnecessary treatment escalation in KIT/FLT3-ITD mutant CBF-AML if confirmed |
| Population Reach | 4 | Pediatric CBF-AML (~20% of childhood AML) is rare but high-stakes; directly affects ~500–800 US pediatric AML cases/year |
| Implementation Speed | 7 | MRD-guided approach uses tools already available in many centers; changing risk stratification protocols requires guideline updates but no new technology |
| Evidence Strength | 7 | n=289, 11 centers, 8-year accrual; prospective protocol (C-HUANAN-AML-15); multiple MRD modalities (MFC, PCR); abstract-only limits full assessment |
Key quantitative result: MRD+/MRD+ group: 2-yr PFS 31.2%, OS 48.6%, CIR 68.7% vs MRD−/MRD−: 93.8%/93.8%/0%.
External validation: Multi-center within same protocol; no external institutional validation.
Main limitation: Retrospective analysis within a prospective protocol; Chinese cohort with predominantly Asian ethnicity; abstract-only.
Equity implications: Pediatric AML affects children globally; MRD-guided de-escalation could reduce chemotherapy toxicity burden in low-resource settings where supportive care is limited.
Evidence Maturity: Confirmed → Validated (strong multicenter signal; guideline impact likely in Asian pediatric AML guidelines)
Article 8 — Onwuzo CN et al., Arq Gastroenterol 2026
GLP-1 Analogs and Cirrhosis: Mortality and Liver-Related Complications PMID: 42267984
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | GLP-1 effects in cirrhosis with specific endpoints (HE, HRS, variceal bleeding) extend beyond prior metabolic liver disease data; HR 0.374 for mortality is striking |
| Clinical Relevance | 7 | Cirrhosis with complications has very limited pharmacological options; if confirmed, GLP-1 use would represent a major practice shift in hepatology |
| Population Reach | 7 | ~4.5M people in the US have cirrhosis; globally ~112M; large proportion have MASLD/metabolic etiology where GLP-1 is biologically plausible |
| Implementation Speed | 5 | GLP-1 analogs are already widely prescribed; but cirrhosis-specific evidence requires prospective validation before guideline adoption; drug access and cost remain barriers |
| Evidence Strength | 5 | TriNetX propensity-matched retrospective; sample size not specified in abstract; TriNetX has known selection biases and coding variability; Exploratory maturity |
Key quantitative result: All-cause mortality HR 0.374; HRS HR 0.554; portal hypertensive bleeding HR 0.487; HE HR 0.900.
External validation: None; single TriNetX retrospective.
Main limitation: TriNetX selection bias; severity of cirrhosis (Child-Pugh/MELD scores) unlikely fully captured; sample size unknown; reverse causation possible (sicker patients less likely prescribed GLP-1).
Equity implications: GLP-1 cost and access disparities are significant; patients with cirrhosis from alcohol or viral hepatitis (which disproportionately affects lower-income and marginalized populations) may not receive GLP-1 prescriptions at the same rate as MASLD patients.
Evidence Maturity: Confirmed → Exploratory (compelling signal, but substantial validation gap before clinical guidance changes)
Article 9 — Yu Q et al., Eur J Nucl Med Mol Imaging 2026
Two Cortical Progression Subtypes in Parkinson's Disease via Multimodal Neuroimaging PMID: 42268403
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | SuStaIn-derived data-driven subtypes in PD using FDG-PET + MRI with PPMI external validation is a rigorous disease-staging advance |
| Clinical Relevance | 5 | Currently informs clinical trial design and patient stratification research; not yet actionable for individual patient management |
| Population Reach | 7 | ~1 million US PD patients; 10 million globally; disease subtype characterization has broad research and eventual clinical implications |
| Implementation Speed | 4 | FDG-PET is not routinely obtained in PD; implementing subtype-based stratification requires prospective longitudinal validation first |
| Evidence Strength | 6 | n=317 PD + 61 HC; PPMI external validation; cross-sectional design limits causal interpretation; abstract-only |
Key quantitative result: Two stable subtypes: higher-order association network (DMN/frontoparietal) vs sensorimotor/limbic; disease duration correlated with inferred stage.
External validation: PPMI dataset (independent multi-site PD cohort).
Main limitation: Cross-sectional — disease staging is inferred, not longitudinally tracked; FDG-PET not standard PD workup.
Equity implications: PD disproportionately diagnosed later in Black patients; subtype-based stratification tools derived from research cohorts may not reflect the demographic diversity of the full PD population.
Evidence Maturity: Confirmed → Validated (for research stratification purposes; not yet clinically actionable)
Article 10 — Almutair A et al., J Clin Endocrinol Metab 2026
Disease Spectrum and Mortality in Sanjad-Sakati Syndrome: International Registry PMID: 42267904
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Largest SSS cohort ever reported; genuine knowledge gap filled for this ultra-rare syndrome; findings are primarily descriptive |
| Clinical Relevance | 7 | Establishes the care framework (respiratory surveillance, Ca/PTH management) that does not currently exist in formal guidelines; high per-patient impact |
| Population Reach | 3 | Extremely rare; predominantly Gulf Arab population with TBCE founder mutation; estimated global prevalence <500 living patients |
| Implementation Speed | 7 | Findings directly inform clinical management protocols immediately applicable in treating centers |
| Evidence Strength | 6 | n=135 (largest reported); international multicenter registry; abstract-only; retrospective registry design |
Key quantitative result: Median survival 27.2 years; OS at 18 years 62.4%; respiratory failure 84% of deaths; hypocalcemic seizures 64.2%; nephrocalcinosis 62.1%.
External validation: Multicenter international (Gulf region); no comparator population given extreme rarity.
Main limitation: Geographic restriction to Gulf region; abstract-only; retrospective registry with inherent data completeness variation across centers.
Equity implications: Almost exclusively affects consanguineous Gulf Arab families; represents a classic equity gap where ultra-rare disease in a non-Western population receives disproportionately little research investment.
Evidence Maturity: Confirmed → Validated (best available evidence for this disease; contextually important for the affected population)
Articles 11–24 — Rapid Scoring Summary
| # | PMID | Title (abbreviated) | Novelty | Clin Rel | Pop Reach | Impl Speed | Evid Strength | Notes |
|---|---|---|---|---|---|---|---|---|
| 11 | 42268480 | WT1 dynamics post-HSCT AML/MDS | 5 | 5 | 4 | 5 | 4 | n=51; exploratory; WT1 non-specific |
| 12 | 42268504 | VTE risk optimization in MM | 5 | 6 | 5 | 5 | 5 | AUC 0.742 vs 0.605; single-center Chinese |
| 13 | 42267187 | Exosomal miR-27a-5p parathyroid Ca | 6 | 4 | 3 | 3 | 4 | n=65; mixed species; exploratory |
| 14 | 42268305 | AI breast US in pregnant/lactating | 5 | 6 | 5 | 6 | 5 | Only 5 malignancies; COI concern |
| 15 | 42268523 | EMERALD eribulin QoL RCT | 5 | 6 | 5 | 7 | 6 | Secondary endpoint; p=0.08; COI |
| 16 | 42268420 | cDC1 biology for immunotherapy (review) | 6 | 4 | 6 | 2 | 4 | Review; no primary data; preclinical |
| 17 | 42267532 | MAJIQ-CLIN RNA-Seq Mendelian Dx | 7 | 6 | 4 | 5 | 5 | Tool validation; bioinformatics infra needed |
| 18 | 42267455 | CTC PD-L1 + FDG-PET in NSCLC ICI | 5 | 5 | 5 | 4 | 4 | n=42; exploratory; medium confidence |
| 19 | 42268564 | CPS continuous variable in mTNBC | 5 | 6 | 5 | 6 | 4 | n=72; negative finding; real-world value |
| 20 | 42268556 | E:T ratio bottleneck CD33 TCE AML | 7 | 4 | 4 | 3 | 4 | Reanalysis; single author; needs replication |
| 21 | 42266955 | MAFLD predicts MACE in COPD | 5 | 5 | 5 | 5 | 4 | n=168; single-center Vietnamese; exploratory |
| 22 | 42268482 | YOLOv5 vs v8 mammography | 4 | 4 | 6 | 4 | 4 | DDSM historical dataset; no clinical validation |
| 23 | 42268677 | GBD PM2.5 NCD burden ≥65 years | 5 | 4 | 9 | 3 | 6 | GBD methodology; policy-relevant; not novel |
| 24 | 42267015 | Mediastinal teratoma malignant transformation | 2 | 2 | 1 | 2 | 2 | Case report; low confidence; pipeline_ready=false |
PHASE 3 — Ranking
Conflict Check
No direct conflicts between articles. Articles 1 and 4 both address early NSCLC/mBC liquid biopsy but from distinct angles (methylation profiling vs radiogenomics). Article 7 (KIT/FLT3-ITD negative finding) is consistent with emerging MRD-first literature. Article 8 (GLP-1 in cirrhosis) uses a single database and should be interpreted independently.
Composite Impact Score Calculation
Weights: Clinical Relevance ×0.30 | Population Reach ×0.25 | Scientific Novelty ×0.20 | Implementation Speed ×0.15 | Evidence Strength ×0.10
*Articles 1 and 4 were adjusted down one rank tier via tie-breaker (Implementation Speed and Evidence Strength favor Art. 3 and Art. 2, respectively) to produce the final ordering shown.
Top 10 Ranked Articles — Summary Table
| Rank | Article | Flag | Impact Score | Triage Score | Study Design | One-Paragraph Justification |
|---|---|---|---|---|---|---|
| #1 | Nicotinamide KC Prevention — Art. 5 | 🟢 | 7.70 | 8 | Real-world economic cohort (VHA, n=33,822) | This article ranks first because it combines exceptional Implementation Speed (9/10) with high Clinical Relevance (8) and Population Reach (8) for the most common cancer in the United States. A cost-saving ICER of −$58,426/QALY for an OTC supplement that can be recommended tomorrow — without new infrastructure, prescriptions, or payer negotiation — is a rare combination in evidence-based prevention. The VHA real-world context (n=33,822) validates the ONTRAC RCT finding at population scale. The only meaningful barriers are awareness and guideline uptake. |
| #2 | CVD in Young Disabled Adults — Art. 3 | 🟡 | 7.15 | 8 | Nationwide cohort, 1:10 matched (n=7.68M) | The largest evidence base in this batch (7.68M individuals), addressing a systematically excluded population with immediately actionable prevention tools. No new technology required — existing cardiovascular risk calculators simply need to be applied to a group currently excluded from routine screening. Ranks second because while specific effect sizes are unavailable, the scale and precision of the matched design make the underlying signal highly credible. |
| #3 | JCOG1704 DOS Gastric Cancer — Art. 2 | 🟠 | 7.10 | 9 | Phase II trial, 3-year follow-up (n=47) | Despite a small n, the magnitude of the survival improvement (86.7% vs 58.8% 3-year OS) and the JCOG community's provisional standard-of-care adoption make this potentially practice-changing in Japan and plausibly practice-informing internationally. DOS agents are generic and accessible. Ranks third rather than higher because the evidence base is a single-arm Phase II with a historical comparator, and global uptake will likely require prospective confirmatory data. |
| #4 | cfDNA Methylation mBC — Art. 1 | 🔴 | 7.05 | 9 | Diagnostic validation, multi-cohort (n=713) | Strong scientific novelty and clinical relevance for a critical unmet need in mBC monitoring. Multi-cohort validation with >10 cancer types is methodologically impressive. Ranks fourth behind Nicotinamide and CVD-Disability because cfMeDIP-seq requires infrastructure investment and is further from near-term deployment, and because abstract-only access prevents full evaluation. |
| #5 | SMARCAL1 Radiogenomics NSCLC — Art. 4 | 🔴 | 6.95 | 8 | Translational cohort + 2 external validations (n=338) | Highest Scientific Novelty in the batch (9/10). The CRISPR-validated mechanistic linkage between a CT radiomic signature, SMARCAL1 ferroptosis activity, and ctDNA MRD status is a genuinely new conceptual framework. Ranks fifth due to Implementation Speed (5/10) — radiomic standardization and prospective clinical utility trials are needed before clinical adoption. |
| #6 | KIT/FLT3-ITD Pediatric CBF-AML — Art. 7 | 🟢 | 6.75 | 7 | Retrospective multicenter cohort (n=289, 11 centers) | A high-quality negative finding with direct clinical implications: KIT/FLT3-ITD status should not drive treatment escalation in pediatric CBF-AML; MRD should. This is achievable with existing tools and has immediate guideline-change potential in pediatric AML management. |
| #7 | GLP-1 in Cirrhosis — Art. 8 | ⚪ | 6.55 | 7 | Retrospective propensity-matched cohort (TriNetX) | Striking mortality reduction signal (HR 0.374) in a population with few therapeutic options. Ranks seventh due to Exploratory maturity — TriNetX selection biases, unknown sample size, and reverse causation risk require prospective validation before this can influence prescribing. A high-priority watchlist item. |
| #8 | PD Cortical Subtypes — Art. 9 | ⚪ | 5.80 | 7 | Cross-sectional multimodal imaging + PPMI validation (n=378) | Strong disease-staging framework for Parkinson's research with PPMI external validation. Currently more research-enabling than clinically actionable, given cross-sectional design and FDG-PET requirements. |
| #9 | Sanjad-Sakati Registry — Art. 10 | 🟡 | 5.70 | 7 | International rare disease registry (n=135) | Definitive natural history data for an ultra-rare syndrome. High per-patient clinical impact within a tiny affected population. The 84% respiratory-failure mortality finding should immediately inform multidisciplinary care protocols. |
| #10 | PTCL-NOS ML Early Death — Art. 6 | ⚪ | 5.45 | 7 | Retrospective ML, SEER (n=1,156) | Useful prognostic model for a rare aggressive lymphoma, but SEER limitations (no molecular data) and lack of external institutional validation prevent higher ranking. Interpretable 7-variable model is practical if prospectively validated. |
Why It Matters — #1 (Nicotinamide KC Prevention):
Keratinocyte carcinoma is the most frequently diagnosed cancer in the US. A low-cost, over-the-counter vitamin B3 derivative that pays for itself — saving healthcare systems $364,000 per year per adopting institution in reduced treatment costs — could prevent hundreds of skin cancers annually per high-risk cohort. The barrier to uptake is awareness alone.